SEARCH

SEARCH BY CITATION

Additional supporting information may be found in the online version of this article at the publisher's web-site.

FilenameFormatSizeDescription
jcph231-sm-0003-Suptab-S1.pdf114KTable S1. Reasons Why the Sponsors and the PMDA Considered the Pharmacokinetics of mAbs to be “Non-Similar”

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.